Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints

Published:2016-10-19 Issue:4 Volume:59 Page:703-731
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biom. J.

Author:

Asakura Koko¹²,Hamasaki Toshimitsu¹²,Evans Scott R.³

Affiliation:

1. Department of Data Science; National Cerebral and Cardiovascular Center; Suita Osaka 565-8565 Japan

2. Department of Innovative Clinical Trials and Data Science; Osaka University Graduate School of Medicine; Suita Osaka Japan

3. Center for Biostatistics in AIDS Research, Department of Biostatistics; Harvard T. H. Chan School of Public Heath; Boston MA 02115 USA

Funder

Japan Society for the Promotion of Science

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bimj.201600026/fullpdf

Reference41 articles.

1. Group-sequential designs when considering two binary outcomes as co-primary endpoints;Asakura,2015

2. Sample size determination in group-sequential clinical trials with two co-primary endpoints;Asakura;Statistics in Medicine,2014

3. Statistical monitoring of clinical trials with multiple co-primary endpoints using multivariate B-value;Cheng;Statistics in Biopharmaceutical Research,2014

4. Challenge of multiple co-primary endpoints: a new approach;Chuang-Stein;Statistics in Medicine,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerate vaccine development using seamless phase 2/3 trial designs;Expert Review of Vaccines;2024-05-07

2. Group sequential two‐stage preference designs;Statistics in Medicine;2023-11-27

3. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents;World Psychiatry;2023-01-14

4. Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials: An adaptive group sequential design with two binary alternative primary endpoints;Communications in Statistics - Theory and Methods;2023-01-03

5. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes;Contemporary Clinical Trials;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3